Creation of 170 jobs to monitor the safety of COVID-19 vaccines

Dublin, 2nd December 2020 - IQVIA, a leading global provider of advanced analytics, technology solutions and clinical research services to the life sciences industry, today announced the creation of 170 remote jobs throughout Ireland.

The company is recruiting in the areas of medical information and pharmacovigilance with a focus on delivering these services in support of the commercial launch of vaccines indicated for COVID-19. Recent graduates and seasoned professionals interested in making a worthwhile contribution to the global fight against COVID-19 are encouraged to apply.

With recruitment under way, IQVIA expects to fill the jobs before the end of March 2021, though there is potential for more roles to be created as the year progresses.

Welcoming the announcement Tánaiste and Minister for Enterprise, Trade and Employment Leo Varadkar TD said “There have been some positive indications recently regarding the potential for a COVID-19 vaccine and although there is still some way to go, it’s important that we plan now. IQVIA is doing excellent work on drug safety and I am really pleased to see that they are creating an additional 170 jobs, specifically to prepare for coronavirus vaccines. It is encouraging that these roles will be available to staff working remotely.”

Head of Pharmacovigilance Oversight and Analytics for IQVIA Ireland, Barry Mulchrone, said, "We are proud to play a role in the humanitarian effort to ensure the safety profile of vaccines used for COVID-19 are monitored to the highest international standards. With more than two decades of experience monitoring the safety of medicines globally, our company in Ireland is well positioned to play its part in addressing the current global pandemic.”

Commenting on the announcement Martin Shanahan, CEO IDA Ireland said: “IQVIA’s ambitious and exciting plans to add 170 new remote working positions in the coming months allows the company to access talent and skills right across all of Ireland’s regions. The life sciences industry in Ireland has demonstrated real leadership this year in the global fight against COVID-19 across research, dynamic supply chain responses, high value manufacturing and business services and support. This announcement by IQVIA is most welcome and points to Ireland’s reputation as a global centre of excellence for life sciences.”   

Present in Ireland since 1990, IQVIA pioneered the country as a hub for clinical research. These additional positions will reinforce IQVIA’s capability to fight the pandemic, ensuring vaccines administrated post authorization are safe for the public. In addition to supporting life sciences in their clinical efforts across Europe and the globe, IQVIA’s activity in Ireland includes supporting the life sciences industry from R&D through to commercialization, as well as healthcare providers, to improve treatment outcomes and patient pathways.    

Notes:

  • Pharmacovigilance, also known as drug safety monitoring, is the pharmacological science relating to the collection, detection, assessment, tracking, and prevention of adverse effects with medicines. Medical information involves handling technical enquiries, product complaints and adverse events associated with medicines.
  • To apply to help advance COVID-19 research, visit https://jobs.iqvia.com/covid-19-jobs 

About IQVIA
IQVIA (NYSE:IQV) is a leading global provider of advanced analytics, technology solutions and clinical research services to the life sciences industry. Formed through the merger of IMS Health and Quintiles, IQVIA applies human data science — leveraging the analytic rigor and clarity of data science to the ever-expanding scope of human science — to enable companies to reimagine and develop new approaches to clinical development and commercialization, speed innovation and accelerate improvements in healthcare outcomes. Powered by the IQVIA CORE™, IQVIA delivers unique and actionable insights at the intersection of large-scale analytics, transformative technology and extensive domain expertise, as well as execution capabilities. With approximately 68,000 employees, IQVIA conducts operations in more than 100 countries.

IQVIA is a global leader in protecting individual patient privacy. The company uses a wide variety of privacy-enhancing technologies and safeguards to protect individual privacy while generating and analyzing information on a scale that helps healthcare stakeholders identify disease patterns and correlate with the precise treatment path and therapy needed for better outcomes. IQVIA’s insights and execution capabilities help biotech, medical device and pharmaceutical companies, medical researchers, government agencies, payers and other healthcare stakeholders tap into a deeper understanding of diseases, human behaviors and scientific advances, in an effort to advance their path toward cures. To learn more, visit www.iqvia.com.